Urakov Aleksandr L, Urakova Natalya A, Yagudin Ilnur I, Svetova Milena D, Suntsova Darya O
Izhevsk State Medical Academy, Kommunarov str., 281, Izhevsk, Russia, 426034.
Udmurt Federal Research Center, Ural Branch of the Russian Academy of Sciences, 34 Tatiana Baramzina Street, Izhevsk, Russia, 426067.
Bioimpacts. 2022;12(4):393-394. doi: 10.34172/bi.2022.23877. Epub 2022 Jun 30.
COVID-19 causes non-specific pneumonia, which has become a new cause of hypoxia, leading to the death of many patients. Today, there are no effective drugs that provide an urgent increase in blood oxygenation. Therefore, it is urgently necessary to develop drugs to increase blood oxygenation in order to save the lives of patients with the new coronavirus infection. Since hypoxia develops in this disease due to the blockage of respiratory tract with viscous mucus and sputum, an appropriate experimental model is needed for screening and finding new drugs. However this model is yet missing. Therefore, the development of an experimental model of respiratory obstruction by sputum with traces of blood can accelerate the discovery of drugs that eliminate hypoxia and prevent the death of patients with nonspecific pneumonia complicated by respiratory obstruction. The purpose of this letter was to present a model for evaluating the biological activity of drugs, which can become a new vector for the development of effective ways to increase blood oxygenation across pulmonary and save the lives of patients with severe atypical pneumonia complicated by respiratory obstruction in COVID-19.
新冠病毒病导致非特异性肺炎，这已成为缺氧的新病因，致使众多患者死亡。如今，尚无能迅速提高血液氧合的有效药物。因此，迫切需要研发提高血液氧合的药物，以挽救新冠病毒感染患者的生命。由于该病中的缺氧是因呼吸道被黏稠黏液和痰液阻塞所致，故而需要一个合适的实验模型来筛选和发现新药。然而，此模型尚不存在。因此，建立伴有微量血液的痰液所致呼吸阻塞的实验模型，能够加速发现消除缺氧并防止并发呼吸阻塞的非特异性肺炎患者死亡的药物。本信函的目的是提出一种评估药物生物活性的模型，该模型可成为开发有效提高肺内血液氧合及挽救新冠病毒病并发呼吸阻塞的重症非典型肺炎患者生命的新途径的载体。
